BOISE, Idaho — The Food and Drug Administration is one step closer to approving a prescription CBD oil. Participants in an Idaho case study may have played a role in the decision-making process.
A panel of federal advisers unanimously voted last week to recommend the approval of the Epidiolex, the first prescription cannabidiol medicine, to treat severe forms of epilepsy.
Epidiolex is a pharmaceutical brand of CBD oil, a cannabis derivative that lacks the psychoactive compound found in marijuana.
Forty Idaho children diagnosed with epilepsy have been part of the state’s Expanded Access Program. Children in the program are legally allowed to use Epidiolex under the care of a doctor. Their progress while using the drug is documented.